Product Portfolio

Featured Products

Our product portfolio features several leading products, including Rasuvo®, Metoject®, RupallTM, Gliolan®, and Treosulfan. Through our business development strategy, we are also actively licensing and/or acquiring new products to supplement our growing pipeline.

Medexus Pharma USA RX Products

Rasuvo®

Rasuvo is a once-weekly, subcutaneous, single-dose auto-injector of methotrexate indicated for the treatment of rheumatoid arthritis, psoriasis and juvenile idiopathic arthritis (JIA).

Learn About Rasuvo

Ixinity®

Ixinity [coagulation factor IX (recombinant)] is a medicine used to replace clotting factor (factor IX) that is missing in adults and children at least 12 years of age with hemophilia B.  

Learn About Ixinity

Medexus Pharma Canada Prescription Products

Metoject®

Metoject is a pre-filled syringe of methotrexate indicated for the treatment of rheumatoid arthritis and psoriasis

Learn About Metoject
Rupall™

Rupall™

Rupall is indicated for the treatment of Seasonal Allergic Rhinitis (SAR), Perennial Allergic Rhinitis (PER) and Chronic Spontaneous Urticaria (CSU) in patients 2 years of age and older.

For Health Care Professionals: For information about Rupall™ please consult the product monograph

For patients:  for information about Rupall™ please consult the patient medication information section of the product monograph

Gliolan®

Gliolan®

Gliolan is an orally administered drug used for the visualization of certain brain tumors.

Treosulfan

Treosulfan

Treosulfan is a conditioning agent used prior to stem cell transplantation.

Cuvposa™ (Glycopyrrolate Oral Solution)

Cuvposa™ (Glycopyrrolate Oral Solution)

Cuvposa™ (Glycopyrrolate) is indicated to reduce chronic severe drooling in patients aged 3 –18 years with neurologic conditions associated with problem drooling (e.g., cerebral palsy).

For Health Care Professionals: for information about Cuvposa™ please consult the product monograph, click here

For patients: For information about Cuvposa™ please consult the patient medication information section of the product monograph

Pediapharm Naproxen Suspension TM  (Naproxen)

Pediapharm Naproxen Suspension TM (Naproxen)

Pediapharm Naproxen Suspension (naproxen) is indicated for the treatment of the signs and symptoms of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and juvenile rheumatoid arthritis. Pediapharm Naproxen Suspension (naproxen) is indicated for the relief of minor aches and pains in muscles, bones and joints, mild to moderate pain accompanied by inflammation in musculoskeletal injuries (sprains and strains) and primary dysmenorrhea.

For Health Care Professionals: for information about Pediapharm Naproxen Suspension™ , please consult the product monograph.

For patients:  for information about Pediapharm Naproxen Suspension™, please consult the consumer information section of the product monograph

Otixal™ (Ciprofloxacin & Flucinolone acetonide)

Otixal™ (Ciprofloxacin & Flucinolone acetonide)

Otixal™ otic solution is indicated for the treatment of acute otitis media with tympanostomy tubes (AOMT) in pediatric patients (age 6 months and older) due to Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Moraxella catarrhalis and Pseudomonas aeruginosa.

Otixal™ is a trademark from Salvat, Spain

For Health Care Professionals: for information about Otixal™ please consult the product monograph

For patients:  for information about Otixal™ please consult the patient medication information section of the product monograph

Medexus Pharma Canada Over the Counter Products

Nyda®

Nyda® is a topical revolutionary treatment indicated for eradication of head lice (Pediculus humanus capitis). Extremely safe to use, it penetrates deeply into the tiniest parts of the lice, larvae and also the egg’s breathing system, replacing the air, and therefore provoking death in all three stages, from eggs to adult lice.

For Health Care Professionals: For information about Nyda®, please consult the product Monograph

For patients:  For information about Nyda®, please consult consumer information section of the product Monograph

Learn About Nyda®

Relaxa™

Relaxa™ (polyethylene glycol 3350 or PEG 3350) is an osmotic laxative used to treat occasional constipation in adults. Relaxa™ works with your body by retaining water in the stool to gently relieve constipation. It is available in Canada with or without a prescription, has a well-established safety and efficacy profile, dissolves completely in any beverage and has no taste, no odor and no unpleasant gritty texture.

For Health Care Professionals: for information about Relaxa™, please consult the prescribing information  click here

For patients:  For information about Relaxa™, please consult consumer information section of the prescribing information

Learn About Relaxa™

Oralvisc®

Oralvisc® helps to reduce joint pain and improves joint function in osteoarthritis of the knee.  It helps support joint health.

The efficacy of Oralvisc® has been clinically proven. Oralvisc® consists of a proprietary ingredient HA Leptin which: lowers leptin levels, reduces inflammation, reduces joint discomfort and improves joint mobility.

Learn About Oralvisc®

Tricovel®

Tricovel® Tablets with Biogenina® help to continuously reduce hair shedding due to Telogen Eflluvium, in 2 months of treatment, promote normal hair growth and normal hair re-growth in Telogen Effluvium. Tricovel® Tablets with Biogenina® help strengthen hair and help increase hair volume.

Learn About Tricovel®

Calcia®

Calcia Calcium & vitamin D has been available worldwide for over 30 years! Calcia is available in 3 smoothchew flavors (orange, lemon, spearmint) and in different combinations of elemental calcium/vitamin D (lactose free and gluten free).

Learn About Calcia®

These products may not be right for you. Always read and follow the label.

The contents of this site are for informational purposes only and are not intended, nor should they be used, as a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician, pharmacist or other qualified health care provider with any questions you may have regarding a medical condition and/or the use of these products. Also read the product monograph and/or the consumer information provided with the product.

Portfolio by Growth Phase

Portfolio by Growth Phase

*Percentages are of the Company’s revenue as disclosed in the condensed interim consolidated statements of loss and comprehensive income (unaudited) of the Company for the nine-month period ended December 31, 2019, as filed on SEDAR, plus the pro-forma impact of Ixinity, as if the acquisition had been completed at the beginning of the fiscal year.